



October 16, 2026

To whom it may concern:

Company Name:	TOHO HOLDINGS CO.,LTD.
Corporate Representative:	Hiromi Edahiro, Representative Director, President and CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact	Makoto Kawamura, Senior Executive Corporate Officer and General Manager, Corporate Strategy Division (TEL: 81-3-6838-2803)

Announcement of Investment in AdipoSeeds, Inc.

TOHO HOLDINGS CO.,LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro; hereinafter "TOHO HOLDINGS") hereby announces that it has invested in AdipoSeeds, Inc. (Headquarters: Tokyo; CEO and CFO: Junji Fuwa; hereinafter "AdipoSeeds"), a venture company spun off from Keio University School of Medicine that develops regenerative medicine products utilizing platelets, as outlined below.

1. Purpose of investment

TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the Group slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

AdipoSeeds was established in July 2016, based on the research results of Professor Yumiko Matsubara, current Visiting Professor at Keio University School of Medicine's Sports Medical Research Center, et al. Based on Professor Matsubara's technologies related to platelet production from non-hematopoietic stem cells, platelet preparation, evaluation, and preservation, AdipoSeeds aims to become a "global pioneer in platelet-based regenerative medicine" by solving the challenges facing platelet-related medical care worldwide with its unique technologies.

Through this investment, TOHO HOLDINGS will support AdipoSeeds' research and development while working to strengthen our portfolio of regenerative medical and cell therapy products.

2. Overview of AdipoSeeds

- (1) Company name: AdipoSeeds, Inc.
- (2) Location: 35 Shinanomachi, Shinjuku-ku, Tokyo (within Keio University School of Medicine)
- (3) Representative: Junji Fuwa, CEO and CFO
- (4) Established: July 7, 2016
- (5) Business content: AdipoSeeds focuses on (i) the development of regenerative medicine products (such as treatments for intractable skin ulcers and platelet preparations for transfusion) using ASCL-PLC, a multifunctional platelet derived from adipose tissue, and (ii) PRP (Platelet-Rich Plasma) business.
- (6) Capital: 110 million yen (As of June 2026)

3. Forward looking outlook

While we expect that this transaction will have only a negligible impact on consolidated earnings of TOHO HOLDINGS, we believe that it will contribute to enhancing the Group's corporate value over the medium to long term. The Company will disclose any impact promptly if it becomes necessary to do so in the future.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
--